Immunotherapy with programmed cell death 1/ligand 1 (PD-1/PD-L1) checkpoint inhibitors has expanded a previously limited pool of effective treatment options for patients with metastatic urothelial carcinoma, particularly those with recurring or refractory disease and those who are ineligible for cisplatin. This review reports key findings from completed and ongoing clinical trials that highlight the potential of PD-1/PD-L1 blockade in urothelial carcinoma. A literature search was performed of PubMed, Embase, ClinicalTrials.gov, and selected annual congress abstracts. Prospective studies, reviews, editorials, and descriptions of ongoing antiePD-1/PD-L1 studies in bladder cancer were included. AntiePD-1/PD-L1 monoclonal antibodies have shown efficacy and safety across patient subgroups with urothelial carcinoma, including those with poor prognostic factors. Efficacy was similar across different antiePD-1/PD-L1 agents. Although these antibodies have demonstrated durable responses in a subset of patients with urothelial carcinoma, clinicians are currently unable to predict which patients may derive benefit from immune checkpoint blockade. AntiePD-1/PD-L1 antibodies have shown favorable clinical activity and tolerability in patients with metastatic urothelial carcinoma refractory to platinum-based therapy or who are ineligible for cisplatin. The activity of PD-1/PD-L1 inhibitors is now also being studied as first-line monotherapy in cisplatin-eligible patients in combination with chemotherapy as maintenance therapy after first-line chemotherapy, and in earlier disease states, such as muscle-invasive and nonemuscle-invasive bladder cancer. Better predictive tools to define target patient populations are needed, as are further investigations to define optimal combinations or sequencing of treatments.
Introduction
Urothelial carcinoma of the bladder and upper tract represents 4.6% of new cancer cases worldwide, predominantly in elderly men. [1] [2] [3] Cytotoxic therapies have been the dominant treatment modality for these cancers for the past 40 years. 4 The most commonly used first-line regimens include gemcitabine plus cisplatin and dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in cisplatin-eligible patients, which result in a median survival of 14 to 15 months. 5, 6 However, for patients with known negative prognostic factors, such as poor Eastern Cooperative Oncology Group (ECOG) performance status (PS) and baseline visceral metastases, these treatments provide minimal survival benefit, as shown by real-world evidence-based analyses in patients with advanced urothelial carcinoma. 7, 8 Approximately half of patients with metastatic disease are ineligible for cisplatin-based therapies as a result of renal impairment, poor ECOG PS, or other comorbidities. First-line treatment options for these patients include carboplatin-based combinations or other noneplatinum-containing chemotherapy regimens that show response rates and survival outcomes that are comparable to, although less efficacious than, cisplatin-based therapies. 9 Vinflunine has been approved as a treatment option for recurrent disease in Europe 10, 11 ; in the United States, this patient population has typically received paclitaxel, docetaxel, gemcitabine, pemetrexed, or other monotherapy or combination chemotherapy. 4, 12 The high prevalence of tumor somatic mutations in advanced urothelial carcinoma, 13 which may generate neoantigens recognized by activated antitumor T cells, 14 provides a rationale for assessing immune checkpoint inhibitors in this disease. Immunotherapy with bacillus Calmette-Guérin alone or in combination with interferon (IFN)-a has been used to treat urothelial cancers since the 1980s, although the associated clinical benefit is limited to noninvasive muscle bladder cancer. [15] [16] [17] Nevertheless, these therapies helped to establish urothelial carcinoma as immunogenic, and CD4 þ T cells, CD8 þ cytotoxic T cells, and natural killer cells have been shown to drive antitumor activity in response to bacillus Calmette-Guérin therapy. 17 The current treatment landscape for urothelial carcinoma is rapidly advancing (Figure 1 ). Antibodies targeting programmed cell death 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1), enhance antitumor T-cell immunity by blocking inhibitory signals generated by these immune checkpoint proteins. 18 Between
May 2016 and May 2017, the US Food and Drug Administration (FDA) granted accelerated approval for use of atezolizumab, durvalumab, and avelumab (monoclonal antiePD-L1 antibodies) and nivolumab (a monoclonal antiePD-1 antibody) for patients with locally advanced or metastatic urothelial carcinoma that had recurred after platinum-containing chemotherapy (provided for first-line metastatic disease or within 12 months of neoadjuvant or adjuvant chemotherapy for muscle-invasive bladder cancer [MIBC] ); another monoclonal antiePD-1 antibody, pembrolizumab, has received full FDA approval in this setting. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Atezolizumab and pembrolizumab were also granted accelerated approval by the FDA for the first-line treatment of cisplatin-ineligible patients. 19, [28] [29] [30] Preclinical studies support the use of checkpoint inhibitors in urothelial carcinoma and have shown that blocking the PD-1/PD-L1 interaction increases the numbers and cytolytic activity of tumor-specific T cells, and modulates levels of proinflammatory and anti-inflammatory cytokines ( Figure 2 ). 
PD-1/PD-L1 Inhibitors in Urothelial Carcinoma
Although tumor PD-L1 expression is used as a biomarker to predict response to antiePD-1/PD-L1 treatments in cancers such as nonesmall-cell lung cancer (NSCLC), 33 clinicians are currently unable to predict which patients with advanced urothelial carcinoma are most likely to benefit from immune checkpoint blockade, and better predictive tools are needed in standard clinical practice. 34 The FDA has approved the Ventana PD-L1 SP142 and SP263 complementary immunohistochemistry (IHC) assays to detect PD-L1 protein expression levels on tumor-infiltrating immune cells (IC [SP142 antibody]) and on tumor cells (TC) and ICs (SP263 antibody) in formalin-fixed, paraffin-embedded tissues, based on assays identifying patients with metastatic urothelial carcinoma as most likely to respond to either atezolizumab (IMvigor 210, described below) or durvalumab in single-arm trials. 19, 20, 23, 24, 35 The safety and efficacy of atezolizumab and durvalumab are not dependent on this assay; therefore, the FDA did not mandate its use as a companion diagnostic tool. 19, 24 Other experimental biomarkers of interest include soluble mediators such as cytokines, chemokines, and tumor antigenespecific antibodies in blood; tumor mutational burden and neoantigens in tumor tissues; and gene signature expression within the tumor microenvironment. 36 We review the role of antiePD-1/PD-L1 checkpoint inhibitors and major clinical trials in the treatment of urothelial carcinoma.
Materials and Methods
We conducted a literature search using PubMed, Embase, ClinicalTrials.gov, and selected Web sites of annual congress abstracts (American Society of Clinical Oncology, European Society for Medical Oncology, European Cancer Congress, Genitourinary Cancers Symposium, Society for Immunotherapy of Cancer, American Urological Association, and European Association of Urology). The search dates queried were January 1, 2011, to May 1, 2017, and original articles of prospective studies and descriptions of ongoing studies pertaining to the use of immunotherapy regimens in urothelial carcinoma were reviewed. Additional articles and congress abstracts published after these search dates were manually queried on the basis of relevance. The following search terms were used to identify publications of interest: "PD-L1" and "PD-1," and relevant generic and investigational drug names of immune checkpoint inhibitors: atezolizumab/MPDL3280A, avelumab/MSB0010718C, durvalumab/MEDI4736, nivolumab/BMS-936558, and pembrolizumab/MK-3475. Additional query search terms were "bladder," "urothelial," "carcinoma," and "cancer," and we limited our search to peer-reviewed articles written in English ( Figure 3 ).
Results

AntiePD-1/PD-L1 Clinical Trials Reported to Date
The potential of PD-1/PD-L1 blockade in bladder cancer and urothelial carcinoma has been observed in multiple clinical trials (Tables 1 and 2) . 22, 27, 29, 30, 35, [37] [38] [39] [40] [41] [42] [43] AntiePD-1/PD-L1 monoclonal antibodies have generally shown manageable safety profiles and have been associated with encouraging durability and tumor response rates in patients with metastatic urothelial carcinoma (Table 1) . 20, 22, 23, 25, 27, 29, 35, 37, 38, 40, 41, 44 Ongoing trials are assessing the efficacy of first-and second-line use of antiePD-1/PD-L1 therapies for all stages of bladder cancer, including noninvasive muscle bladder cancer, MIBC, and metastatic urothelial carcinoma ( Table 2 ). We present a chronological summary of phase 1, 2, and 3 trials that are assessing efficacy and safety of antiePD-1/PD-L1 antibodies in the following disease settings: after progression of platinum-refractory metastatic urothelial carcinoma (after first-line or after perioperative treatment), and in cisplatin-ineligible patients with metastatic urothelial carcinoma.
Second-Line AntiePD-1/PD-L1 Therapies After Progression on Platinum-Based Chemotherapy Phase 1 Studies. Atezolizumab was the first antiePD-1/PD-L1 antibody observed to show antitumor activity in urothelial carcinoma, based on findings from a phase 1 trial of 85 platinum-treated chemotherapy-resistant patients (NCT01375842), although these findings were not confirmed in the subsequent phase 3 study described below. 42 In the phase 1 study, responses were associated with PD-L1 expression on ICs, and patients with higher PD-L1 expression (IHC 2/3) had an objective response rate (ORR) of 46% compared to 16% in patients with low PD-L1 expression (IHC 0/1) ( patients with unresectable locally advanced or metastatic urothelial carcinoma after the failure of a platinum-containing regimen. 21 Durvalumab showed a manageable safety profile and evidence of clinical activity in a phase 1 expansion cohort of 191 patients with advanced disease that had progressed during or after any number of prior therapies (NCT01693562) ( Table 1) . 39 JAVELIN Solid Tumor (NCT01772004) is a phase 1 dose-expansion trial designed to investigate the clinical activity and safety of avelumab in patients with metastatic solid tumors, including urothelial carcinoma (Table 1 ). An initial cohort of avelumab-treated patients with advanced urothelial carcinoma that had progressed after platinum chemotherapy showed encouraging antitumor responses and a manageable safety profile (n ¼ 44). 25 An additional efficacy cohort of 205 patients with advanced urothelial carcinoma was enrolled in the JAVELIN study. A pooled analysis of the initial and efficacy cohorts, which constituted the basis of the FDA's accelerated approval of avelumab for this patient population, resulted in an ORR of 17% in those patients at ! 6 months' follow-up, with 82% of responses ongoing at the time of data cutoff. 40 The ORR in patients with or without baseline visceral metastases was 14% compared to 38%, respectively. The disease of patients with historically poor prognostic factors also responded to avelumab, although with decreased response rates, and there was a trend toward lower ORR in patients with increased Bellmunt risk score. 45 ORR was 3% and 21% in patients with low and normal levels of albumin at baseline and 4% and 20% in patients with baseline hemoglobin levels of < 10 g/dL compared to > 10 g/dL, respectively. Despite a trend of PD-L1epositivity associated with clinical activity in the initial cohort of patients with metastatic urothelial carcinoma, antitumor activity could not be linked to PD-L1 expression on the basis of the pooled analysis. With a ! 5% cutoff for staining on TCs, the ORR was 25% in patients with PD-L1epositive tumors and 13% in patients with PD-L1enegative tumors (P ¼ .082); median PFS was 12 versus 6 weeks in PD-L1epositive and PD-L1enegative patients, respectively. Median OS in all postplatinum avelumab-treated patients was 7 months. TRAEs of any grade occurred in 67% of patients and included infusion-related reactions, fatigue, and rash in ! 10% of patients; 7% of patients had grade 3 or higher TRAEs, including fatigue in ! 1% of patients. Similarly, a phase 1 cohort of 33 PD-L1epositive patients (TC or stromal) with advanced urothelial carcinoma that had progressed after prior systemic therapies showed preliminary antitumor activity with pembrolizumab (KEYNOTE-012; NCT01848834) ( Table 1) . 41 In 27 evaluable patients with measurable disease at baseline, ORR was 26%, with ongoing responses in 7% of patients at the time of data cutoff. In a post hoc analysis of PD-L1 expression, 56% of patients had PD-L1epositive TCs. When ICs were also included in this scoring, a larger population of patients (84%) was considered PD-L1 positive. The ORR in the subset of evaluable patients with PD-L1epositive or enegative staining in TCs and ICs was 24% and 0, respectively. Median OS for all patients was 13 months. Adverse events were common, with TRAEs of any grade, including fatigue and peripheral edema, occurring in 60% of patients. Grade 3 or higher events included elevated AST level, myalgia, myositis, dehydration, hypercalcemia, thrombocytopenia, rhabdomyolysis, neuromyopathy, toxic encephalopathy, and maculopapular and pruritic rash in 15% of patients.
PD-1/PD-L1 Inhibitors in Urothelial Carcinoma
Phase 2 Studies. Given the encouraging reports of antitumor activity and safety in phase 1 studies, phase 2 and phase 3 trials have subsequently been conducted to further characterize efficacy of antiePD-1/PD-L1 therapies in larger populations of patients with advanced urothelial carcinoma. After the previously reported phase 1 study of atezolizumab in 85 patients, a separate large phase 2, single-arm study (IMvigor 210; NCT02108652) (Table 1) confirmed the efficacy of atezolizumab as second-line therapy in an expanded cohort of 310 patients with metastatic urothelial carcinoma that had progressed after chemotherapy. 20, 35 ORR was 16% in patients unselected for PD-L1 expression, whereas patients in the IC1/2/3 (! 1%) and IC2/3 (! 5%) PD-L1 expression subgroups had ORRs of 19% and 28%, respectively. Median OS was 7.9 months in the overall population, 11.4 months in the IC2/3 group, and 8.8 months in the IC1/2/3 group. The safety profile of atezolizumab was consistent with that seen in the phase 1 trial, 37, 44 and TRAEs of any grade occurred in 70% of patients, with fatigue, nausea, decreased appetite, and pruritus in ! 10% of patients. Grade 3 or higher TRAEs occurred in 16% of patients, with fatigue the most common, at 2%. The FDA granted accelerated approval of atezolizumab for patients with locally advanced or metastatic urothelial carcinoma that progressed during or after any platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant chemotherapy based on the IMvigor 210 second-line results. 19 A subsequent phase 3 study (IMvigor 211) failed to confirm these studies and did not meet its primary end point of OS; a confirmatory trial assessing clinical efficacy and safety of atezolizumab in cisplatin-ineligible patients is ongoing. CheckMate 275 (NCT02387996) is a phase 2 study that investigated the efficacy and safety of nivolumab in 265 patients with metastatic urothelial carcinoma who had received prior treatment. 22 ORR was 20% in all patients, and 16% and 24% in patients with tumors with negative ( 1%) and positive (> 1%) PD-L1 expression on TCs, respectively. Responses were ongoing in 77% of patients with disease that responded to therapy at last follow-up, and median OS was 8.7 months in the overall population and 6.0 versus 11.30 months in PD-L1enegative versus PD-L1epositive patients. The safety analysis of CheckMate 275 showed that grade 3 or higher TRAEs occurred in 18% of patients, with fatigue and diarrhea occurring in 2% of patients each. The encouraging safety and efficacy observed in this study were the basis for FDA accelerated approval of nivolumab in the second-line setting. 21 Phase 3 Studies. With multiple phase 1 and 2 trials completed, ongoing phase 3 trials have further distinguished the efficacy and safety of antiePD-1/PD-L1 agents in urothelial carcinoma. KEYNOTE-045 (NCT02256436) (Table 2), a randomized phase 3 trial that compared pembrolizumab with investigator choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in 542 patients with metastatic or advanced urothelial carcinoma that recurred or progressed after platinum-based chemotherapy, showed an ORR for pembrolizumab of 21% compared to 11% for chemotherapy. 27, 43 OS, regardless of PD-L1 expression, was superior with pembrolizumab compared to chemotherapy (10.3 vs. 7.4 months), and there was a 30% reduction in the risk of death. 43 In the subgroup of patients with enriched PD-L1 expression (! 10%), median OS was longer in the pembrolizumabtreated arm compared to the chemotherapy-treated arm (hazard ratio of 0.57), and a similar trend was noted for patients with low PD-L1 expression (< 10%). 43 There was no difference in PFS in patients treated with either pembrolizumab or chemotherapy in the overall population 43 and according to PD-L1 expression status (hazard ratio 0.89). 27 Pembrolizumab was tolerated better than chemotherapy; 61% of patients in the pembrolizumab arm compared to 90% of patients in the chemotherapy arm experienced TRAEs of any grade, including those of grade 3 or higher (17% and 50% for pembrolizumab and chemotherapy, respectively). 43 Results from KEYNOTE-045 led to full FDA approval for treatment of this patient population with metastatic urothelial carcinoma. 28 IMvigor 211 (NCT02302807), a randomized phase 3 study that compared atezolizumab with investigator choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in the postplatinum setting, enrolled 932 patients. ORR for both atezolizumab-and chemotherapy-treated patients was 13%. Although atezolizumab treatment provided a benefit over chemotherapy with a median OS of 8.6 months versus 8.0 months, respectively (P ¼ .038), the trial failed to achieve its primary objective in showing superiority of atezolizumab compared to chemotherapy based on PD-L1 expression in the IC2/3 subgroup. In patients with high PD-L1 expression (IC2/3; ! 5% staining), atezolizumab and chemotherapy regimens resulted in OS of 11.1 and 10.6 months, respectively (P ¼ .41). Median OS in the atezolizumab and chemotherapy arms was 8.9 versus 8.2 months in the IC1/2/3 subgroup (! 1% PD-L1 expression; P ¼ .14). The safety profile was consistent with that seen in previous studies of atezolizumab; TRAEs of all grades occurred in 70% versus 89% of patients treated with atezolizumab and chemotherapy, respectively; grade 3/4 TRAEs occurred in 20% versus 43% of atezolizumab-and chemotherapy-treated patients. 42 First-Line AntiePD-1/PD-L1 Therapies in Cisplatin-Ineligible Patients. Many patients are unable to tolerate standard-of-care firstline treatment of advanced urothelial carcinoma with cisplatin because of impaired renal function, poor PS, or other comorbidities. 46 To address this population of patients, IMvigor 210, the same phase 2 study of atezolizumab that assessed a population of postplatinum patients with metastatic urothelial carcinoma, enrolled a second cohort of 119 cisplatin-ineligible patients who received atezolizumab as first-line treatment. 20, 29 30, 47 resulted in an ORR of 29%, with high-level PD-L1 expression predicting patients with disease most likely to respond to treatment. Moreover, ORR in patients with tumor PD-L1 expression of ! 10% was 37%. TRAEs of any grade were common in these pembrolizumab-treated patients (66%), 19% of whom had a grade 3 or higher event. 47 On the basis of these studies, both atezolizumab and pembrolizumab were granted accelerated approval by the FDA for first-line treatment of cisplatin-ineligible patients.
19,28-30
Combination Immunotherapy in ChemotherapyRefractory Urothelial Carcinoma
Multiple agents, including other immunotherapy, targeted therapy, chemotherapy, and radiotherapy, may enhance the immune response to checkpoint inhibition. The combination of checkpoint inhibitors targeting different molecules, such as PD-L1 and CTLA-4, may enhance the antitumor efficacy seen with monotherapy in urothelial carcinoma. In addition to testing nivolumab as a monotherapy in previously treated patients, CheckMate 032 tested therapy with 2 combination schedules of ipilimumab plus nivolumab (nivolumab 1 mg/kg þ ipilimumab 3 mg/kg [N1I3; n ¼ 26] or nivolumab 3 mg/ kg þ ipilimumab 1 mg/kg [N3I1; n ¼ 104]) and yielded early encouraging clinical responses. ORR was 39% and 26% in the N1I3 and N3I1 cohorts compared to 26% for nivolumab monotherapy; median OS for the combination was 10.2 and 7.3 months for N1I3 and N3I1, respectively. Safety was consistent with that of nivolumab monotherapy (grade 3 or higher TRAEs occurred in 31% and 23% of patients treated with N1I3 and N3I1, respectively, compared to 23% for nivolumab monotherapy). 48 Several ongoing phase 1/2 studies are addressing the combination approach with other novel therapies in patients with advanced or metastatic urothelial carcinoma that has progressed after previous platinum-based therapy. A phase 1 trial (NCT02496208) has shown clinical response to the doublet combination of cabozantinib plus nivolumab (n ¼ 30) or the triplet combination of cabozantinib plus nivolumab plus ipilimumab (n ¼ 18) in previously treated patients with metastatic urothelial carcinoma or other genitourinary tumors. Treatment was tolerable; the most common grade 3 or higher adverse events were neutropenia, elevated lipase level, hypophosphatemia, and fatigue in patients treated with the doublet combination; and hypophosphatemia, elevated ALT level, hypertension, elevated lipase level, and fatigue in patients treated with the triplet combination (! 10% of patients). ORR was 37% for all genitourinary tumors and 44% for patients with urothelial carcinoma, with all patients with urothelial carcinoma experiencing ongoing responses at the time of data cutoff. 49 Phase 1 studies with combination regimens with pembrolizumab include a phase 1a/b trial that enrolled 24 patients who were treated with a combination of pembrolizumab and the antievascular endothelial growth factor receptor 2 antibody ramucirumab. 50 Preliminary ORR was 8%. TRAEs occurred in 54% of patients, most commonly fatigue, nausea, pyrexia, and elevated ALT and AST levels in ! 10% of patients (3 patients [13%] had grade 3 TRAEs). Pembrolizumab with either docetaxel or gemcitabine has also been assessed in 12 patients with advanced or metastatic urothelial carcinoma that progressed on ! 1 previous platinum-based therapies. 51 Encouraging antitumor activity was noted in this study, particularly with pembrolizumab plus docetaxel (ORR 50%); ORR was 17% for the pembrolizumab plus gemcitabine regimen. The overall incidence of grade 3 or higher TRAEs was 54%, most commonly anemia, fatigue, and neutropenia. ECHO-202/KEYNOTE-037 (NCT02178722) is a phase 1/2 study of pembrolizumab plus epacadostat, an inhibitor of indoleamine 2,3-dioxygenase 1, in multiple advanced cancers, including a cohort with urothelial carcinoma that has enrolled 40 patients. In a preliminary analysis, ORR was 35%, and 7 of 11 patients with PD-L1epositive tumors had a response (ORR, 64%). Grade 3/4 TRAEs occurred in 23%.
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Safety Profile for AntiePD-1/PD-L1 Agents in Metastatic Urothelial Carcinoma
In addition to the encouraging efficacy results demonstrated in several clinical trials, antiePD-L1 agents have also been associated with fewer adverse events compared to chemotherapy. 20, 22, 23, 25, 29, 30, 38, 40, 41, 44 Although serious TRAEs, renal toxicity, and serious immune-related adverse events affecting the dermatologic, gastrointestinal, hepatic, and endocrine systems have been noted in patients with metastatic urothelial carcinoma receiving treatment with antiePD-1/PD-L1 agents, they are reported less frequently than during treatment with chemotherapy regimens. 53 Indeed, immunotherapy appears to be generally better tolerated than chemotherapy, including in elderly patients or patients with comorbidities who have historically had limited treatment options due to toxicity. 1, 46 Despite the general tolerability of antiePD-1/ PD-L1 antibodies, challenges associated with their use include acquired resistance attributable to upregulation of alternative immune checkpoints, a phenomenon noted in other tumor types. 54 
Treatment Sequencing and Combination Treatment Strategies With AntiePD-1/PD-L1 Agents
Combination regimens with antiePD-1/PD-L1 agents and platinum-based chemotherapy for patients with metastatic urothelial carcinoma are also being evaluated in phase 3 trials (Table 2) . KEYNOTE-361 is assessing efficacy and safety of first-line pembrolizumab treatment with or without platinum-based chemotherapy in patients with advanced or metastatic urothelial carcinoma, compared to platinum-based chemotherapy (cisplatin with gemcitabine or carboplatin with gemcitabine doublet) in treatment-naive patients with metastatic urothelial carcinoma. 55 CheckMate 901
(NCT03036098) will assess the efficacy of nivolumab in combination with ipilimumab versus platinum-based chemotherapy in patients with untreated inoperable or metastatic urothelial carcinoma. 56 DANUBE will determine the efficacy and safety of first-line durvalumab treatment with or without tremelimumab versus platinum-based chemotherapy in cisplatin-eligible and -ineligible patients. 57 IMvigor 130 is analyzing first-line treatment with atezolizumab plus gemcitabine/carboplatin chemotherapy versus placebo plus gemcitabine/carboplatin in a cohort of randomized cisplatin-ineligible patients with advanced metastatic urothelial carcinoma. 58 After completion of first-line platinum-based chemotherapy without progressive disease, patients are typically managed with best supportive care (BSC) because effective maintenance regimens resulting in durable responses in these patients have not been established. Maintenance treatment thus offers the possibility of prolonging PFS in patients who achieve a response to first-line chemotherapy. However, there are currently no approved agents for maintenance treatment of patients with metastatic urothelial carcinoma. In a recent phase 2 study of 88 patients with advanced urothelial carcinoma who achieved stable disease after first-line cisplatin and gemcitabine treatment (MAJA, SOGUG 2011/02; NCT01529411), maintenance vinflunine resulted in longer PFS compared to BSC. 59 Median PFS was 6.5 months in patients treated with maintenance vinflunine compared to 4.2 months in those patients receiving BSC (hazard ratio of 0.59). Although patients treated with vinflunine maintenance had an increased incidence of adverse events versus those treated with BSC, all grade 3/4 adverse events were manageable. Maintenance treatment with checkpoint inhibitors for controlled urothelial carcinoma is also being assessed in several studies; a phase 2 study of pembrolizumab as maintenance therapy after initial chemotherapy in urothelial carcinoma is currently ongoing (NCT02500121). 60 Furthermore, a phase 3 study of maintenance therapy with avelumab plus BSC compared to BSC in patients with metastatic urothelial carcinoma that did not worsen during or after first-line treatment with platinum-based chemotherapy (JAVELIN Bladder 100; NCT02603432) is also ongoing. 61 Combination therapy for patients with metastatic urothelial carcinoma who have failed at least one prior platinum regimen is also being assessed in BISCAY (NCT02546661), a biomarker-directed multidrug umbrella study combining next-generation targeted small molecules and durvalumab. 62 Cisplatin-based neoadjuvant chemotherapy is standard with radical cystectomy, given the high risk of relapse with surgery alone. 63 In the neoadjuvant setting, multiple trials with immune checkpoint inhibitors are ongoing or planned. Among these studies are two phase 2 studies that are currently enrolling patients to receive atezolizumab (NCT02662309) or pembrolizumab (NCT02736266), with pathologic complete response as the primary end point. 64, 65 In the adjuvant setting after radical cystectomy for MIBC, there is currently no standard treatment, 4 and adjuvant treatment with antiePD-1/ PD-L1 therapies for these patients is being assessed in several phase 3 trials. IMvigor 010 and CheckMate 274 are assessing adjuvant treatment with atezolizumab and nivolumab, respectively. In IMvigor 010, patients with PD-L1eselected MIBC who are at high risk for recurrence after cystectomy will be treated with atezolizumab or observation. In CheckMate 274, these patients will be randomized and treated with nivolumab or placebo and stratified by PD-L1, lymph node, and previous cisplatin neoadjuvant chemotherapy status. 66 Finally, an intergroup trial of pembrolizumab versus observation in the adjuvant treatment of MIBC and high-grade upper tract urothelial carcinoma has initiated enrollment (AMBASSADOR; NCT03244384).
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Evidence for Potential Biomarkers
PD-L1 as a Predictive Biomarker
Levels of tumor PD-L1 expression have been associated with urothelial carcinoma severity and treatment outcome; thus, assessment of PD-L1 expression has consistently been an integral part of clinical studies of checkpoint inhibitors in urothelial carcinoma. 20, 22, 25, 29, 35, 37, 38, 40, 41 The use of PD-L1 as a biomarker in bladder cancer is complex as a result of several factors, including heterogeneity of PD-L1 expression level within tumors, variability in tissue collection requirements across trials (fresh or archival samples), differences among antibody clones used for IHC, definitions of PD-L1 positivity based on protocol-specific staining cutoffs, and use of nonstandardized test designs. 34 There are currently several PD-L1 assays used in trials for each of the antiePD-1/PD-L1 inhibitors described in this review. Although the Ventana PD-L1 assay (SP142; OptiView DAB IHC detection kit with OptiView amplification) stains both TCs and ICs, the FDA approved it as a complementary assay for atezolizumab on the basis of the clinical benefit that was associated with enriched IC PD-L1 staining in 310 postplatinum patients from IMvigor 210. 19, 20, 35 However, the FDA's accelerated approval of atezolizumab did not include a requirement for PD-L1 expression testing, 4, 19 and indeed, no significant enrichment of response by PD-L1 expression was seen in the cohort of first-line, cisplatin-ineligible patients treated with atezolizumab, in contrast to responses from the postplatinum patient cohort. 29 Although analyses are ongoing, top-line results from IMvigor 211 suggest that the biomarker was not indicative of clinical efficacy. 42 In KEYNOTE-012 and KEYNOTE-052, pembrolizumab showed enhanced antitumor activity in patients with recurrent or metastatic PD-L1epositive urothelial carcinoma based on ! 1% and ! 10% PD-L1 expression, respectively. 30, 41, 47 PD-L1 was assessed using the Dako PD-L1 IHC 22C3 pharmDx assay, a qualitative IHC assay using the antiePD-L1 clone 22C3 performed on formalin-fixed, paraffin-embedded tissues, which is currently approved by the FDA as a companion diagnostic test to identify patients with NSCLC for treatment with pembrolizumab. 28 Durvalumab showed enhanced antitumor activity in a population of patients with ! 25% PD-L1 expression on ICs or TCs as a combined measure. PD-L1 was assessed using the FDA-approved Ventana SP263 PD-L1 assay, which stains TCs and ICs at a threshold of ! 25%. Notably, PD-L1 expression was not predictive of durvalumab efficacy when assessed in TCs or ICs separately but was predictive of efficacy when assessed in TCs and ICs combined. 23 In the JAVELIN Solid Tumor trial of avelumab, testing has been performed using the proprietary Dako PD-L1 IHC 73-10 pharmDx assay. Although potential differences in efficacy per PD-L1 expression have been seen, durable efficacy has also been observed in PD-L1enegative subgroups. 25, 40 The role of tumor PD-L1 expression has similarly been investigated across several nivolumab trials, and phase 1 and 2 nivolumab trials used the Dako PD-L1 IHC 28-8 pharmDx assay to determine TC PD-L1 expression at ! 1% or ! 5% staining and at any intensity. These studies showed that patients with PD-L1enegative and PD-L1epositive tumors benefited equally. 22, 38 Despite wide usage of PD-L1 in clinical trials, its predictive role in urothelial carcinoma remains uncertain, with trends suggesting different clinical outcomes by PD-L1 expression based on staining in ICs, TCs, or both. Furthermore, each of the PD-L1 assays has been designed for use with a specific inhibitor, and it is currently unknown whether these assays are interchangeable. Although one recent study reported that in NSCLC, the 22C3, 28-8, and E1L3N antiePD-L1 antibodies appeared to be interchangeable, 68 this has not been verified in urothelial carcinoma. The ongoing FDA Blueprint initiative for companion diagnostics, whose goal is to standardize analytical and clinical performance across various PD-L1 diagnostic assays, was undertaken to address this controversy. 69 
Next-Generation Predictive Biomarkers
In addition to tumor PD-L1 expression, mutational load has been explored for its association with clinical outcomes in patients treated with PD-1/PD-L1 checkpoint inhibitors. 70 Other biomarkers that may predict response to immunotherapies include IFN-g gene signatures, expanded immune gene signatures, and tumor subtypes based on The Cancer Genome Atlas (TCGA). 71, 72 Studies to identify peripheral blood immune biomarkers have determined that blockade of the PD-1/PD-L1 axis can increase effector T-cell proliferation and production of inducible T-cell a chemoattractant, IFN-g, and interleukin 18, although these responses were not indicative of significant response or progression. 72 The TCGA project analyzed gene expression data sets relative to clinical and pathologic data in chemotherapy-naive patients with MIBC. As part of these analyses, bladder cancer subtypes were grouped on the basis of luminal-and basal-like gene signatures. 71 Further analyses revealed that certain TCGA subtypes were associated with prognostic differences in survival, with basal tumors associated with decreased survival. 73 IMvigor 210 and CheckMate 275 included analyses of urothelial carcinoma subtype and immune gene signature expression as predictive biomarkers. 20, 22 In IMvigor 210, TCGA molecular subtypes were independently associated with clinical responses to atezolizumab. IC PD-L1 expression was highly enriched in the basal urothelial carcinoma subtype, which also had the strongest IFN-g gene signature expression, compared to the luminal subtype. Additionally, mutational burden was significantly higher in responders than in nonresponders. CheckMate 275 also showed an association between high IFN-g expression and urothelial carcinoma molecular subtype with clinical outcome of nivolumab treatment. 22 Finally, the BISCAY trial is exploring whether the addition of targeted small molecules to durvalumab treatment in patients with specific biomarkers may result in enhanced neoantigen release and immunosensitization. 62 
Health-Related Quality of Life as a Marker of Treatment Benefit With Immune Checkpoint Inhibitors
Measurement of patient-reported outcomes, including health-related quality of life (HRQOL), is a rapidly expanding initiative that has been included as an end point in multiple clinical trials after validation of self-report questionnaires. There are growing amounts of data supporting the benefit of immune checkpoint inhibitors relative to HRQOL measures reported by patients with urothelial carcinoma, and nearly all ongoing phase 3 trials for patients with urothelial carcinoma have begun to incorporate HRQOL measures as key secondary objectives. For example, in KEYNOTE-045, pembrolizumab was associated with improved HRQOL measures compared to chemotherapy, including increased rates of improvement for most social functioning and symptom domains (31.2% vs. 22.0%) and lower rates of deterioration for all social functioning and symptom domains (28.9 vs. 40.6%). 74 IMvigor 211 measured patient-reported global health status, physical functioning, and fatigue occurring during treatment with atezolizumab based on European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 quality-of-life questionnaires. In evaluable patient-reported outcomes, an overall numerical trend toward better global health status and less fatigue was seen with atezolizumab. Mean global health status scores worsened initially but returned to baseline values more quickly with atezolizumab than with chemotherapy. Similar results were seen for physical functioning. Furthermore, the initial worsening of fatigue levels rapidly improved with atezolizumab. 42 Additionally, IMvigor 130 will also measure median time to deterioration during atezolizumab treatment based on EORTC QLQ-C30 reports, and disease-related symptoms and health status of patients with metastatic urothelial carcinoma will be assessed in JAVELIN Bladder 100 (avelumab) and DANUBE (durvalumab).
57,61
Conclusion
Bladder cancer remains an area of great unmet medical need, with 5-year OS rates of 5% for metastatic disease. 1 Although platinumbased combination chemotherapy leads to high response rates in patients with urothelial carcinoma, most of these patients will ultimately experience disease progression. Therefore, improved treatments for advanced or metastatic urothelial carcinoma must still be determined. 4 The recent approvals of antiePD-1/PD-L1 therapies have expanded the treatment landscape for patients with bladder cancer, for whom there have been few options with durable responses. Additional examination of data from recent trials may prompt repeat evaluation of key study design assumptions made, given the success of KEYNOTE-045 and the failure of IMvigor 211 to meet its primary end point. 27, 28, 42 AntiePD-1/PD-L1 monoclonal antibodies have shown efficacy and safety in patients with advanced disease, particularly in those with poor prognostic factors. In general, efficacy appears to be similar among different antiePD-1/PD-L1 agents tested to date in populations unselected for PD-L1 status, although head-to-head data are not available. Differences have been seen between the predictive value of different assays used for PD-L1 detection, consistent with the use of different antibodies and methodologies in the various trials. Future considerations to improve the probability of benefit provided by PD-1/PD-L1 checkpoint inhibitors include the use of biomarkers or a combination of biomarkers, as well as HRQOL reports, to identify the
